Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Cognitive Dysfunction/cerebrospinal fluid"'
Autor:
Patrick R. Hof, Tatjana Orct, Ena Španić, Koraljka Bačić Baronica, Spomenka Kiđemet-Piskač, Fran Borovečki, Mirjana Babić Leko, Željka Vogrinc, Vesna Lukinović Škudar, Matea Nikolac Perkovic, Goran Šimić, Nela Pivac, Ankica Sekovanić, Jasna Jurasović
Publikováno v:
Journal of Alzheimer's Disease. 82:661-672
Background: The major confirmed genetic risk factor for late-onset, sporadic Alzheimer's disease (AD) is variant ɛ4 of apolipoprotein E gene (APOE). It is proposed that ApoE, a protein involved in transport of cholesterol to neurons can cause neurod
Autor:
Aikaterini Oikonomidi, John Corthésy, Jérôme Wojcik, Gene L. Bowman, Hugues Henry, Antonio Núñez Galindo, Loïc Dayon, Ornella Cominetti, Julius Popp, Eugenia Migliavacca
Publikováno v:
Journal of Alzheimer's Disease, Vol. 60, No 4 (2017) pp. 1641-1652
Journal of Alzheimer's disease, vol. 60, no. 4, pp. 1641-1652
Journal of Alzheimer's disease, vol. 60, no. 4, pp. 1641-1652
Cerebrospinal fluid (CSF) biomarkers of the beta-amyloid and microtubule associated protein tau metabolism have proven the capacity to improve classification of subjects developing Alzheimer's disease (AD). The blood plasma proteome was characterized
Autor:
Naomi De Roeck, Davide Chiasserini, Mareike Müller, Jill Luyckx, Jurgen A.H.R. Claassen, Hanne Struyfs, Francesca Baschieri, Marcel M. Verbeek, Lucilla Parnetti, Sebastiaan Engelborghs, Lucia Farotti, H. Bea Kuiperij, Alexandra A M Versleijen
Publikováno v:
Journal of Alzheimer's disease
Journal of Alzheimer's Disease, 52, 4, pp. 1321-33
Journal of Alzheimer's Disease, 52, 1321-33
Journal of Alzheimer's Disease, 52, 4, pp. 1321-33
Journal of Alzheimer's Disease, 52, 1321-33
Item does not contain fulltext MicroRNAs (miRNAs) regulate translational inhibition of proteins, but are also detected in body fluids, including cerebrospinal fluid (CSF), where they may serve as disease-specific biomarkers. Previously, we showed dif
Autor:
Hanne Struyfs, Ulf Andreasson, Daniëlle Hernalsteen, Erik Portelius, Christine Van Broeckhoven, Kaj Blennow, Eugeen Vanmechelen, Didier De Surgeloose, Dirk Jacobs, Ann De Vos, Henrik Zetterberg, Caroline Robberecht, Erik Fransen, Kerstin Andersson, Kristel Sleegers, Sebastiaan Engelborghs
Publikováno v:
Alzheimer's & Dementia. 11(12):1461-1469
Introduction Biomarkers monitoring synaptic degeneration/loss would be valuable for Alzheimer's disease (AD) diagnosis. Postsynaptic protein neurogranin may be a promising cerebrospinal fluid (CSF) biomarker but has not yet been evaluated as a plasma
Autor:
Perez-Santiago, Josue, De Oliveira, Michelli F, Var, Susanna R, Day, Tyler RC, Woods, Steven P, Gianella, Sara, Mehta, Sanjay R
Publikováno v:
Journal of neurovirology, vol 23, iss 2
Perez-Santiago, Josue; De Oliveira, Michelli F; Var, Susanna R; Day, Tyler RC; Woods, Steven P; Gianella, Sara; et al.(2017). Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals. JOURNAL OF NEUROVIROLOGY, 23(2), 283-289. doi: 10.1007/s13365-016-0497-5. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/98c6k4hz
Perez-Santiago, Josue; De Oliveira, Michelli F; Var, Susanna R; Day, Tyler RC; Woods, Steven P; Gianella, Sara; et al.(2017). Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals. JOURNAL OF NEUROVIROLOGY, 23(2), 283-289. doi: 10.1007/s13365-016-0497-5. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/98c6k4hz
Cell-free mitochondrial DNA (mtDNA) is a highly immunogenic molecule that is associated with several inflammatory conditions and with neurocognitive impairment during untreated HIV infection. Here, we investigate how cell-free mtDNA in cerebrospinal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::11b84aabfa343f47b0bccd3c961dd08a
https://escholarship.org/uc/item/98c6k4hz
https://escholarship.org/uc/item/98c6k4hz
Autor:
Juan Manuel Maler, Johannes Kornhuber, Sebastiaan Engelborghs, Barbara Mroczko, Philipp Spitzer, Lucilla Parnetti, Charlotte E. Teunissen, Sebastian Brandner, Max Holzer, Natalia Lelental, Armand Perret-Liaudet, Davide Chiasserini, Piotr Lewczuk, Henrik Zetterberg, José Luis Molinuevo, Ingolf Lachmann, Julius Popp, Kaj Blennow, Katharina Flach
Publikováno v:
Journal of Alzheimer's Disease, Vol. 55, No 1 (2017) pp. 159-170
Journal of Alzheimer's Disease
Journal of Alzheimer's disease
Journal of Alzheimer's Disease
Journal of Alzheimer's disease
Background: Virtually nothing is known about a potential diagnostic role of non-phospho-epitopes of Tau (Non-P-Tau) in cerebrospinal fluid (CSF). Objective: To establish and analytically and clinically characterize the first assay capable to measure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bea197dd84f75b93e7d8659fb53c95f
https://archive-ouverte.unige.ch/unige:105992
https://archive-ouverte.unige.ch/unige:105992
Autor:
Kaj Blennow, Piotr Lewczuk, Lucilla Parnetti, Bruno Dubois, José Luis Molinuevo, Charlotte E. Teunissen, Armand Perret-Liaudet, Sebastiaan Engelborghs
Publikováno v:
Molinuevo, J L, Blennow, K, Dubois, B, Engelborghs, S, Lewczuk, P, Perret-Liaudet, A, Teunissen, C E & Parnetti, L 2014, ' The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative ', Alzheimers & Dementia, vol. 10, no. 6, pp. 808-817 . https://doi.org/10.1016/j.jalz.2014.03.003
Alzheimer's & dementia
Alzheimers & Dementia, 10(6), 808-817. Elsevier
Alzheimer's & dementia
Alzheimers & Dementia, 10(6), 808-817. Elsevier
Background Cerebrospinal fluid (CSF) biomarkers β-amyloid 1-42 (Aβ 1-42 ), also expressed as Aβ 1-42 :Aβ 1-40 ratio, T-tau, and P-tau 181P , have proven diagnostic accuracy for mild cognitive impairment and Alzheimer's disease (AD). How to use, i
Autor:
Laetitia Aerts, Peter Paul De Deyn, Christine Van Broeckhoven, Sebastiaan Engelborghs, Nathalie Le Bastard, Jean-Jacques Martin, Kristel Sleegers
Publikováno v:
Journal of alzheimers disease, 33(3), 807-822. IOS Press
Journal of Alzheimer's disease
Journal of Alzheimer's disease
The current treatment for Alzheimer's disease (AD) is purely symptomatic, but medications interfering with underlying pathophysiological processes are being developed. To evaluate a possible disease-modifying effect, cerebrospinal fluid (CSF) biomark
Autor:
Naomi De Roeck, Hanne Struyfs, Patrick Cras, Sebastiaan Engelborghs, Jill Luyckx, Jean-Jacques Martin, Ellis Niemantsverdriet, Peter Paul De Deyn, Ellen Elisa De Roeck, Maria Bjerke, Bart De Vil, Joery Goossens, Charisse Somers
Publikováno v:
Journal of Alzheimer's disease
During the past ten years, over 5,000 cerebrospinal fluid (CSF) samples were analyzed at the Reference Center for Biological Markers of Dementia (BIODEM), UAntwerp, for core Alzheimer's disease (AD) CSF biomarkers: amyloid-β peptide of 42 amino acid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aba3fb2001373e40b84aa7258c00f3c
https://hdl.handle.net/20.500.14017/1fe35dec-4068-4c41-8e5e-0868e684c747
https://hdl.handle.net/20.500.14017/1fe35dec-4068-4c41-8e5e-0868e684c747
Autor:
Christine Van Broeckhoven, Dirk Jacobs, Sebastiaan Engelborghs, Ellen Elisa De Roeck, Erik Fransen, Tom Klewansky, Ann De Vos, Caroline Robberecht, Eugeen Vanmechelen, Hanne Struyfs, Charles Duyckaerts
Publikováno v:
Journal of Alzheimer's Disease
Journal of Alzheimer's disease
Journal of Alzheimer's disease
Background: In diagnosing Alzheimer’s disease (AD), ratios of cerebrospinal fluid (CSF) biomarkers, such as CSF Aβ1-42/tau, have an improved diagnostic performance compared to the single analytes, yet, still a limited value to predict cognitive de